Vistagen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
November 09, 2023 at 04:44 pm EST
Share
Vistagen Therapeutics, Inc. reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported revenue was USD 0.2777 million compared to negative revenue of USD 0.8925 million a year ago. Net loss was USD 6.59 million compared to USD 17.48 million a year ago. Basic loss per share from continuing operations was USD 0.66 compared to USD 2.54 a year ago.
For the six months, revenue was USD 0.4553 million compared to negative revenue of USD 0.5825 million a year ago. Net loss was USD 13.49 million compared to USD 37.26 million a year ago. Basic loss per share from continuing operations was USD 1.55 compared to USD 5.41 a year ago.
Vistagen Therapeutics, Inc. is a neuroscience-focused biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for psychiatric and neurological disorders based on its understanding of nose-to-brain neurocircuitry. Its clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies called pherines. Its diversified pipeline of pherine product candidates rapidly activate chemosensory neurons in the nasal cavity to impact fundamental neurocircuitry in the olfactory system and the brain. Its pipeline also includes an oral prodrug with potential to modulate N-methyl-D-aspartate receptor (NMDA) receptor activity. Its neuroscience pipeline includes five clinical-stage investigational agent, namely Fasedienol (PH94B), Itruvone (PH10), AV-101, PH15, PH80, and PH284.